Journal
DIABETES THERAPY
Volume 5, Issue 2, Pages 355-366Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s13300-014-0089-4
Keywords
Anti-diabetic drugs; Cardiovascular safety; Canagliflozin; Dapagliflozin; Empagliflozin; Perineal hygiene; Sodium-glucose co-transporter-2 inhibitors
Categories
Ask authors/readers for more resources
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a newly developed class of oral anti-diabetic drugs (OADs) with a unique mechanism of action. This review describes the biochemistry and physiology underlying the use of SGLT2 inhibitors, and their clinical pharmacology, including mechanism of action and posology. The pragmatic placement of these molecules in the existing OAD arena is also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available